ClinicalTrials.gg
RecruitingNCT07661641Updated Sep 4, 2026

A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors

A Phase 1 interventional study of [68Ga]Ga-A9-6217 and Low dose [177Lu]Lu-A9-0631 in Breast Cancer, Prostate Cancer and Colorectal Cancer, sponsored by Alpha-9 Oncology USA Inc.. Recruiting at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Alpha-9 Oncology USA Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
115
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 402 studies in Breast Neoplasms with a site in Australia — 84 open to participants now, 156 under way, 61 of them phase 3. Breast Neoplasms · Australia.

Planned enrollment
261st of 380
115 · median 253
Started
2026
with 15 others
Phase 1
72 of 402
23 open now
Primary completion
2028-12
later than 121 of 155 live
Registered
396th of 402
by date

Among the 402 studies in Breast Neoplasms with a site in Australia, this one is the 261st largest by planned enrollment of the 380 interventional ones that give a count, is one of 16 that started in 2026, is one of 72 in phase 1, reaches primary completion later than 121 of the 155 other live ones, and was the 396th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

84 of the 402 studies in Breast Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

78 more — sign in →

All 84 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Breast Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 1-1b multicenter clinical study to evaluate the safety, efficacy, and dosimetry of [177Lu]Lu-A9-0631 and [225Ac]Ac-0642 in participants with Gastrin-Releasing Peptide Receptor (GRPR) expressing locally advanced, unresectable or metastatic solid tumors.

Read the detailed description

This is a multicenter, open-label Phase 1-1b study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 in subjects with Gastrin-Releasing Peptide Receptor (GRPR) expressing locally advanced, unresectable or metastatic solid tumors.

The study consists of two parts (Phase 1 and 1b).

Phase 1 is the dose escalation portion of the study. The aim of the Phase 1 is to evaluate the safety and tolerability as well as the normal organ and tumor dosimetry of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D).

Phase 1b will be the dose expansion portion of the study. The aim of the Phase 1b will be to further evaluate the safety, efficacy, and normal organ and tumor dosimetry of [177 Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 administered at the RP2D in subjects with (1) Locally advanced, unresectable, or metastatic HR+/HER2- breast cancer; (2) Locally advanced, unresectable, or metastatic prostate cancer; (3) Locally advanced, unresectable, or metastatic CRC; and (4) Other locally advanced, unresectable, or metastatic GRPR-positive solid tumors.

03

Conditions studied

  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • GRPR-positive Solid Tumors

Keywords

  • breast cancer
  • prostate cancer
  • colorectal cancer (CRC)
  • GRPR-positive solid tumors
  • radiopharmaceuticals
  • theranostics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided written prior to any study-specific procedure.
  • Age ≥ 18 years old.
  • (ECOG) performance status of 0 to 1.
  • Have measurable target lesion per v1.1.
  • Progression from, intolerant to, or ineligible for (due to unavailability or ) local standard of care therapies and have one of the following locally advanced or tumor types: prostate cancer; HR+/- breast cancer; colorectal cancer; and GRPR-positive solid tumors.
  • Have GRPR-expressing disease as confirmed by PET / CT or SPECT imaging.
  • Adequate organ function within 14 days of first administration of therapeutic product.
  • At least 4 weeks from prior major surgery.

Exclusion criteria

Exclusion Criteria:

  • Received anticancer treatment including but not limited to chemotherapy, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs ≤ 14 days prior (≤ 28 days prior in case of therapy and other antibody therapies) or 5 half-lives, (t1/2) whichever is shorter, to the administration of therapeutic product.
  • History of uncontrolled allergic reactions and/or known or expected to a peptide-based imaging or therapeutic agent or any present in either of the therapeutic investigational products.
  • Major surgery within 4 weeks of planned first dose of the therapeutic investigational product.
  • Prior external beam radiation therapy to more than 25% of the bone marrow.
  • Pregnant, breastfeeding, or unwilling to practice during participation in the study.
  • Any active infection.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    Phase 1 Dose Escalation

    Diagnostic Test: [68Ga]Ga-A9-6217 · Diagnostic Test: Low dose [177Lu]Lu-A9-0631 · Drug: [177Lu]Lu-A9-0631 · Drug: [225Ac]Ac-A9-0642

  • Experimental
    Phase 1B Dose Expansion

    Diagnostic Test: [68Ga]Ga-A9-6217 · Diagnostic Test: Low dose [177Lu]Lu-A9-0631 · Drug: [177Lu]Lu-A9-0631 · Drug: [225Ac]Ac-A9-0642

Interventions

  • Diagnostic test[68Ga]Ga-A9-6217

    Administered IV

  • Diagnostic testLow dose [177Lu]Lu-A9-0631

    Administered IV

  • Administered IV

  • Administered IV

06

What researchers measure

Primary outcomes

  1. Phase 1-1b: Incidence of Adverse Events by Frequency, Duration, and Severity

    An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of patients experiencing an AE in Part 1 will be reported.

    Time frame: From the first dose of study drug up to the End of Treatment (30 days after the last dose)

  2. Phase 1: Number of Patients with Dose-Limiting Toxicities (DLTs).

    DLTs is defined as any predefined AE occurring during the DLT observation period.

    Time frame: Up to 28 days following first study treatment

  3. Phase 1: Maximum tolerated dose (MTD)

    Incidence of dose-limiting toxicity (DLT) per dose level of \[177Lu\]Lu-A9-0631 and/or \[225Ac\]Ac-A9-0642.

    Time frame: Up to 28 days following first study treatment

Secondary outcomes

  1. Phase 1-1b: Absorbed dose estimates (Gy) in normal organs for [177Lu]Lu-A9-0631 and/or [225Ac]Ac-A9-0642

    Time frame: Up to 7 days after each injection for up to 6 cycles (each cycle is 28 days)

  2. Phase 1-1b: Objective Response Rate (ORR)

    Objective response rate is defined as the percentage of patients who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator based on RECIST 1.1, by dose level.

    Time frame: Every 8 ± 1 weeks until radiographic disease progression or up to 12 months after the last dose of [177Lu]Lu-A9-0631 and/or [225Ac]Ac-A9-0642

07

Study locations

1 of 2 sites recruiting
  • Melbourne Theranostic Innovation Center
    Melbourne N., Victoria 3051, Australia
    Recruiting
  • GenesisCare Murdoch
    Murdoch, Western Australia 6150, Australia
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 29 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 22, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07661641
Lead sponsor
Alpha-9 Oncology USA Inc.
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jul 1, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Sep 4, 2026

Study contacts

Stephen Hull, MD
Contact
shull@a9oncology.com
+1-778-715-3303
Stephen Hull, MD
study director · Alpha 9 Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lutetium-177 · Actinium-225

Start the discussion